Trial Profile
A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Azacitidine
- Indications Advanced breast cancer; Lymphoma; Solid tumours
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 14 Sep 2016 Status changed from active, no longer recruiting to completed.
- 14 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Feb 2015 Planned End Date changed from 1 Nov 2014 to 1 Nov 2016 as reported by ClinicalTrials.gov record.